Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals - PubMed (original) (raw)
Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals
Thomas S Frank et al. J Clin Oncol. 2002.
Abstract
Purpose: To assess the characteristics that correlate best with the presence of mutations in BRCA1 and BRCA2 in individuals tested in a clinical setting.
Patients and methods: The results of 10,000 consecutive gene sequence analyses performed to identify mutations anywhere in the BRCA1 and BRCA2 genes (7,461 analyses) or for three specific Ashkenazi Jewish founder mutations (2,539 analyses) were correlated with personal and family history of cancer, ancestry, invasive versus noninvasive breast neoplasia, and sex.
Results: Mutations were identified in 1,720 (17.2%) of the 10,000 individuals tested, including 968 (20%) of 4,843 women with breast cancer and 281 (34%) of 824 with ovarian cancer, and the prevalence of mutations was correlated with specific features of the personal and family histories of the individuals tested. Mutations were as prevalent in high-risk women of African (25 [19%] of 133) and other non-Ashkenazi ancestries as those of European ancestry (712 [16%] of 4379) and were significantly less prevalent in women diagnosed before 50 years of age with ductal carcinoma in situ than with invasive breast cancer (13% v 24%, P =.0007). Of the 74 mutations identified in individuals of Ashkenazi ancestry through full sequence analysis of both BRCA1 and BRCA2, 16 (21.6%) were nonfounder mutations, including seven in BRCA1 and nine in BRCA2. Twenty-one (28%) of 76 men with breast cancer carried mutations, of which more than one third occurred in BRCA1.
Conclusion: Specific features of personal and family history can be used to assess the likelihood of identifying a mutation in BRCA1 or BRCA2 in individuals tested in a clinical setting.
Comment in
- Does the search for large genomic rearrangements impact BRCAPRO carrier prediction?
Capalbo C, Buffone A, Vestri A, Ricevuto E, Rinaldi C, Zani M, Ferraro S, Frati L, Screpanti I, Gulino A, Giannini G. Capalbo C, et al. J Clin Oncol. 2007 Jun 20;25(18):2632-4; author reply 2634-5. doi: 10.1200/JCO.2007.11.4330. J Clin Oncol. 2007. PMID: 17577048 No abstract available.
Similar articles
- Mutational analyses of BRCA1 and BRCA2 in Ashkenazi and non-Ashkenazi Jewish women with familial breast and ovarian cancer.
Shiri-Sverdlov R, Oefner P, Green L, Baruch RG, Wagner T, Kruglikova A, Haitchick S, Hofstra RM, Papa MZ, Mulder I, Rizel S, Bar Sade RB, Dagan E, Abdeen Z, Goldman B, Friedman E. Shiri-Sverdlov R, et al. Hum Mutat. 2000 Dec;16(6):491-501. doi: 10.1002/1098-1004(200012)16:6<491::AID-HUMU6>3.0.CO;2-J. Hum Mutat. 2000. PMID: 11102978 - BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer.
Moslehi R, Chu W, Karlan B, Fishman D, Risch H, Fields A, Smotkin D, Ben-David Y, Rosenblatt J, Russo D, Schwartz P, Tung N, Warner E, Rosen B, Friedman J, Brunet JS, Narod SA. Moslehi R, et al. Am J Hum Genet. 2000 Apr;66(4):1259-72. doi: 10.1086/302853. Epub 2000 Mar 16. Am J Hum Genet. 2000. PMID: 10739756 Free PMC article. - Risk factors for detecting germline BRCA1 and BRCA2 founder mutations in Ashkenazi Jewish women with breast or ovarian cancer.
Hodgson SV, Heap E, Cameron J, Ellis D, Mathew CG, Eeles RA, Solomon E, Lewis CM. Hodgson SV, et al. J Med Genet. 1999 May;36(5):369-73. J Med Genet. 1999. PMID: 10353781 Free PMC article. - Identification of germline 185delAG BRCA1 mutations in non-Jewish Americans of Spanish ancestry from the San Luis Valley, Colorado.
Mullineaux LG, Castellano TM, Shaw J, Axell L, Wood ME, Diab S, Klein C, Sitarik M, Deffenbaugh AM, Graw SL. Mullineaux LG, et al. Cancer. 2003 Aug 1;98(3):597-602. doi: 10.1002/cncr.11533. Cancer. 2003. PMID: 12879478 Review. - Hereditary breast cancer in Jews.
Rubinstein WS. Rubinstein WS. Fam Cancer. 2004;3(3-4):249-57. doi: 10.1007/s10689-004-9550-2. Fam Cancer. 2004. PMID: 15516849 Review.
Cited by
- Splicing analysis of 14 BRCA1 missense variants classifies nine variants as pathogenic.
Ahlborn LB, Dandanell M, Steffensen AY, Jønson L, Nielsen FC, Hansen TV. Ahlborn LB, et al. Breast Cancer Res Treat. 2015 Apr;150(2):289-98. doi: 10.1007/s10549-015-3313-7. Epub 2015 Feb 28. Breast Cancer Res Treat. 2015. PMID: 25724305 Free PMC article. - PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective.
Loizzi V, Ranieri G, Laforgia M, Gadaleta CD, Gargano G, Kardhashi A, De Liso M, Naglieri E, Del Vecchio V, Cicinelli E, Cormio G. Loizzi V, et al. Oncol Lett. 2020 Oct;20(4):90. doi: 10.3892/ol.2020.11951. Epub 2020 Aug 6. Oncol Lett. 2020. PMID: 32831909 Free PMC article. Review. - Associations between BRCA Mutations in High-Risk Breast Cancer Patients and Familial Cancers Other than Breast or Ovary.
Noh JM, Choi DH, Baek H, Nam SJ, Lee JE, Kim JW, Ki CS, Park W, Huh SJ. Noh JM, et al. J Breast Cancer. 2012 Sep;15(3):283-7. doi: 10.4048/jbc.2012.15.3.283. Epub 2012 Sep 28. J Breast Cancer. 2012. PMID: 23091540 Free PMC article. - Population-Based BRCA1/2 Testing in Ashkenazi Jews: Ready for Prime Time.
Lynce F, Isaacs C. Lynce F, et al. J Natl Compr Canc Netw. 2016 Jun;14(6):809-12. doi: 10.6004/jnccn.2016.0081. J Natl Compr Canc Netw. 2016. PMID: 27283172 Free PMC article. No abstract available. - Low rates of African American participation in genetic counseling and testing for BRCA1/2 mutations: racial disparities or just a difference?
Halbert CH, Kessler L, Collier A, Weathers B, Stopfer J, Domchek S, McDonald JA. Halbert CH, et al. J Genet Couns. 2012 Oct;21(5):676-83. doi: 10.1007/s10897-012-9485-y. Epub 2012 Jul 12. J Genet Couns. 2012. PMID: 22790832 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous